C
Clene Nanomedicine
Biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases
About Clene Nanomedicine
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing innovative nanotherapeutics to address cellular energy impairments common in neurodegenerative diseases. The company operates in the biopharmaceutical market, primarily serving patients with conditions such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Clene's business model revolves around the development and commercialization of its proprietary nanocrystal-based therapies, with its lead drug candidate, CNM-Au8, currently in clinical trials. The company generates revenue through equity and debt financings, out-licensing of commercial-stage assets, and potential future sales of its therapeutic products. Clene aims to revolutionize the treatment landscape for neurodegenerative diseases by restoring and protecting neuronal health and function.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Salt Lake City, United States
- Listing
- IPO 2020
- Employees
- 71
- Open positions
- None listed
- Dealroom signal
- 45.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Clene Nanomedicine.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $7M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jan 2026 | $28M | — | Vivo Capital · Boxer Capital · Coastlands Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $207K | +3.7% | −$21M | -10178.9% |
| 2025 | $200K | -41.5% | −$21M | -10555.5% |
| 2024 | $342K | -47.7% | −$32M | -9497.4% |
| 2023 | $654K | +38.3% | −$52M | -7958.4% |
| 2022 | $473K | -34.6% | −$45M | -9529.2% |
| 2021 | $723K | +251% | −$48M | -6704.1% |
| 2020 | $206K | — | −$16M | -7770.4% |
Growth signals
Latest recorded traffic for Clene Nanomedicine is 6.5K monthly website visits, up 91.2% over the last three months. Clene Nanomedicine's team grew 4.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series B and later5 investors entered at this stage
SymBiosis
State of Maryland
Vivo Capital
Boxer Capital- CCCoastlands Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Clene Nanomedicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clene Nanomedicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.